Dr. Babbitt has 30 years of industry experience focusing primarily on biologics development. Over the past 8 years he has worked with many biosimilar developers on a broad array of products including filgrastim, infliximab, adalimumab, bevacizumab, trastuzumab, rituximab, and ranibizumab. One of his primary functions is to formulate clinical development plans and support client-FDA meetings. Dr. Babbitt has worked at PAREXEL for over 15 years and previously headed R&D at both LipoGen, Inc. and Cellcor, Inc. He has a PhD in Biochemistry (Univ. of Tennessee) and conducted post doc work in cellular immunology at Harvard and Washington University Medical Schools.